无码一区二区三区视频,特一级大黄A久久久久久久片,黄色污污污日本免费网站,成人网综合视频在线播放

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人：蔣經(jīng)理
電話：4008750250
號碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號
Email： zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73196KIF5B（E15）-RET（E12） V804M/BaF3

KIF5B（E15）-RET（E12） V804M/BaF3
名稱 KIF5B（E15）-RET（E12） V804M/BaF3
型號 CBP73196
報價
特點 KIF5B（E15）-RET（E12） [V804M]/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73196
I. Introduction

Cell Line Name：

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RRPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

CBP73196 WB.png


2. Sanger of KIF5B-RET [V804M]/BaF3

CBP73196 sanger1.png

CBP73196 sanger2.png


3. Anti-proliferation assay


CBP73196 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).




如果你對CBP73196KIF5B（E15）-RET（E12） V804M/BaF3感興趣，想了解更詳細(xì)的產(chǎn)品信息，填寫下表直接與廠家聯(lián)系：


留言框

  • 產(chǎn)品：

  • 您的單位：

  • 您的姓名：

  • 聯(lián)系電話：

  • 常用郵箱：

  • 省份：

  • 詳細(xì)地址：

  • 補(bǔ)充說明：

  • 驗證碼：

    請輸入計算結(jié)果（填寫阿拉伯?dāng)?shù)字），如：三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
亚洲黄色一区999| 网站色欧美日韩国产| 欧美精品精品在线一区| 内射后入日韩电影| 日韩一二三四区在线看| 美女靠逼视频外国| 久久色情影视| 午液影院黄色电影| 好看的一二区欧美日韩| 男人天堂av影院| 欧美日韩伊人大香蕉| 色色色色色911111| 久久久天堂在线| 大美女老骚逼视频| 做狠狠做深爱婷婷久久综合一区| 国产精品亚洲日韩大神4页| 欧美色| 国产成人亚洲欧美综合无| 欧美 一区 三级| 国产一区二区自拍肛交| 黄色影院AV| 欧美成人黄a| 日中韩一级免费做a爱片| 欧美双插电影在线观看| 日韩久久久无码精品亚洲| 91九色 婷婷| 日本人妻丝袜美腿视频| 久久图片亚洲区| 91视频在线欧美| 综合偷拍一区| 国产乱伦乱人一区二区三区| 浦北县| 久久好吊妞精品视频| 88av一区| 日韩在线观看一区二区三区四区 | 亚洲欧美综合国产一区| 欧美破处一级黄片| 日韩美一区二区三区成人免费视频| 丝袜 一区二三区| 久久视频日本片| rihan 大香蕉|